- Home
- KOS vs CDNA Comparison
KOS vs CDNA Comparison
Compare KOS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOS
- CDNA
- Stock Information
- Founded
- KOS 2003
- CDNA 1998
- Country
- KOS United States
- CDNA United States
- Employees
- KOS N/A
- CDNA N/A
- Industry
- KOS Oil & Gas Production
- CDNA Medical Specialities
- Sector
- KOS Energy
- CDNA Health Care
- Exchange
- KOS Nasdaq
- CDNA Nasdaq
- Market Cap
- KOS 817.4M
- CDNA 1.0B
- IPO Year
- KOS 2011
- CDNA 2014
- Fundamental
- Price
- KOS $1.74
- CDNA $15.39
- Analyst Decision
- KOS Strong Buy
- CDNA Buy
- Analyst Count
- KOS 6
- CDNA 7
- Target Price
- KOS $5.18
- CDNA $30.33
- AVG Volume (30 Days)
- KOS 10.8M
- CDNA 1.0M
- Earning Date
- KOS 05-06-2025
- CDNA 04-30-2025
- Dividend Yield
- KOS N/A
- CDNA N/A
- EPS Growth
- KOS N/A
- CDNA N/A
- EPS
- KOS N/A
- CDNA 1.07
- Revenue
- KOS $1,546,854,000.00
- CDNA $346,421,000.00
- Revenue This Year
- KOS $1.22
- CDNA $13.28
- Revenue Next Year
- KOS $9.43
- CDNA $15.13
- P/E Ratio
- KOS N/A
- CDNA $14.29
- Revenue Growth
- KOS N/A
- CDNA 25.92
- 52 Week Low
- KOS $1.39
- CDNA $7.42
- 52 Week High
- KOS $6.33
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- KOS 48.24
- CDNA 38.88
- Support Level
- KOS $1.45
- CDNA $14.09
- Resistance Level
- KOS $1.72
- CDNA $18.71
- Average True Range (ATR)
- KOS 0.13
- CDNA 1.01
- MACD
- KOS 0.02
- CDNA -0.25
- Stochastic Oscillator
- KOS 65.91
- CDNA 24.03
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.